CN101181069A - Compound nutritional protein powder for preventing postmenopausal osteoporosis in women - Google Patents

Abstract

The invention relates to a compound nutritional protein powder for preventing women's postmenopausal osteoporosis. The components and weight percentages thereof are: soybean protein powder 55-80%; whey protein powder 15-35%; soybean isoflavones 0.2-0.8%; oligosaccharides 1-5%; calcium lactate 1.2-2.4%; stabilizer 0.5-1%; lecithin 0.5-1.5%. The product of the invention is safe and reliable to eat, has good effect, has no toxic and side effects, and has no dependence. Regular consumption can protect the health of middle-aged women, especially can improve women's health problems caused by estrogen deficiency, and improve their quality of life and quality of life. , can be used as a protein supplement product that women often consume.

Description

Compound nutritional protein powder for preventing postmenopausal osteoporosis in women

technical field

The invention relates to a compound nutritional protein powder, in particular to a compound nutritional protein powder for preventing postmenopausal osteoporosis in women.

Background technique

With the increase of our country's aging population, osteoporosis has become another disease that threatens our health after cardiovascular disease and cancer. Investigations show that my country is the country with the largest number of osteoporosis patients in the world at present, with about 90 million patients, accounting for about 7% of the total population.

Osteoporosis is particularly harmful to postmenopausal women. After menopause, the level of estrogen in the body of women drops sharply, the inhibition of osteoclasts is weakened, the osteolysis is accelerated, and the bone formation is weakened, resulting in a large loss of bone calcium, which leads to osteoporosis. In my country, the incidence rate of osteoporosis in 60-69-year-old women is as high as 50%-70%. Therefore, how to prevent postmenopausal osteoporosis and prevent fractures is an important topic that we need to pay attention to.

Estrogen replacement therapy (HRT) is the main method to prevent osteoporosis in postmenopausal women. A large number of studies have shown that the application of HRT can prevent postmenopausal osteoporosis very well, but HRT will produce its side effects while preventing osteoporosis , Such as breast cancer, ovarian cancer, cardiovascular disease and gastrointestinal adverse reactions, as well as some women's psychological concerns, cannot be accepted by all women who lack estrogen.

With the further understanding and research on plant-derived estrogen-like substances, pharmacists have become interested in phytoestrogens. At present, phytoestrogens, especially isoflavones, are promoted as "health care products". Soybeans with estrogenic effects, especially the isoflavones in soybeans, have a certain preventive effect on postmenopausal osteoporosis.

Contents of the invention

The purpose of the present invention is to provide a compound nutritional protein powder capable of comprehensively, effectively and safely preventing postmenopausal osteoporosis in women, so as to protect the health of middle-aged women and improve the quality of life and quality of life.

The technical scheme that the present invention takes is:

A compound nutritional protein powder for preventing women's postmenopausal osteoporosis, its composition and weight percentage are respectively:

Soy protein powder 55～80%

Whey protein powder 15-35%

Soybean isoflavones 0.2～0.8%

Oligosaccharides 1～5%

Calcium lactate 1.2～2.4%

Stabilizer 0.5～1%

Lecithin 0.5-1.5%.

Moreover, the soybean protein powder is soybean protein isolate, and its protein content is more than or equal to 60%.

Moreover, the whey protein powder is concentrated whey protein, and its protein content is more than or equal to 60%.

Moreover, the total soy isoflavone content in the said soy isoflavones is more than or equal to 40%.

Moreover, the content of said soy isoflavones is calculated based on the total soy isoflavones content.

Moreover, the oligosaccharides are soybean oligosaccharides or isomaltose oligosaccharides or fructooligosaccharides or lactooligosaccharides or galactooligosaccharides.

Moreover, the stabilizer is xanthan gum or carrageenan, or a mixture of both.

Furthermore, said lecithin is homogenized lecithin.

Advantage and positive effect of the present invention are:

1. The present invention takes soybean protein isolate powder and whey protein powder as the main body, uses the principle of animal and plant protein complementation, mixes soybean protein and whey protein in a certain proportion, and makes the content of the nine essential amino acids closer to what the human body needs. The amino acid mode is easily absorbed and utilized by the human body; in addition, the emulsifier lecithin and the stabilizer xanthan gum or/and carrageenan are added to the formula to make the protein powder have good stability and sensory quality.

2. The present invention strengthens the functional ingredient soybean isoflavones and the oligosaccharides that promote the absorption of soybean isoflavones, thereby achieving the effect of preventing osteoporosis in menopausal women. The preventive effect test on osteoporosis in ovariectomized rats showed that the nutritional protein powder fortified with soybean isoflavones has a preventive effect on osteoporosis in ovariectomized rats.

3. The oligosaccharides added by the present invention can regulate the normal flora of the gastrointestinal tract of the body and produce special enzymes, which can not only promote the reabsorption of endogenous estrogen, improve the level of endogenous estrogen in the body, but also increase the level of endogenous estrogen in the body. The absorption and reabsorption of soy isoflavones have dual effects of increasing endogenous estrogen levels and supplementing exogenous estrogen-like substances, so it has a more significant effect on preventing postmenopausal osteoporosis, menopausal syndrome and breast cancer. Effect.

4. The functional ingredient soy isoflavones of the present invention can alleviate the various discomforts of women's climacteric syndrome, improve sleep; can prevent cardiovascular and cerebrovascular diseases, reduce the occurrence of women's breast cancer, and also have an effect on preventing and treating senile dementia (Alzheimer's disease). Certain utility.

5. The functional component oligosaccharides of the present invention also have the effects of lowering blood fat, lowering blood sugar, and promoting the absorption of mineral elements.

6. Calcium lactate in the present invention is a calcium source, and is easily absorbed by the human body under the presence and action of soybean isoflavones.

7. The lecithin in the present invention has antioxidant and emulsifying effects, which makes the protein powder easier to be digested and absorbed by the human body, and helps the protein to mix, is not easy to form glue blocks, and dissolves faster and better.

8. The product of the present invention is safe and reliable to eat, has good effect, has no toxic and side effects, and has no dependence, and can be used as a protein supplement product that women often eat.

Detailed ways

Below in conjunction with embodiment, the present invention is further described; Following embodiment is illustrative, not limiting, can not limit protection scope of the present invention with following embodiment.

First things first:

Soybean protein powder is soybean protein isolate, and its protein content is ≥60%.

Whey protein powder is whey protein concentrate with a protein content ≥ 60%.

The content of total soybean isoflavones in soybean isoflavones is more than or equal to 40%, and the content of soybean isoflavones is calculated based on the content of total soybean isoflavones.

The oligosaccharides can be one of soybean oligosaccharides, isomaltooligosaccharides, fructooligosaccharides, lactooligosaccharides or galactooligosaccharides.

Embodiment 1: (following each raw material percentage composition is weight percent composition)

Soy protein powder 75%

Whey Protein Powder 25%

Soy Isoflavones 0.3%

Soybean oligosaccharides 3%

Calcium Lactate 2%

Xanthan Gum 0.7%

Lecithin 1%.

Production technology step of the present invention is as follows:

Weigh soybean protein powder, whey protein powder, xanthan gum, calcium lactate, oligosaccharides and homogenized lecithin according to the above weight percentages and mix them. Protein powder produced by phospholipid granulation technology and its preparation method" to produce compound protein powder, collect, add soybean isoflavones, mix, sterilize, aseptically package, 25g sub-package, pack small packs, pack large packs, packing. Inspection, finished product storage.

Embodiment 2: (following each raw material percentage composition is weight percent composition)

Soy protein powder 80%

Whey Protein Powder 20%

Soy Isoflavones 0.5%

Isomaltooligosaccharide 5%

Calcium Lactate 2%

Carrageenan 0.7%

Lecithin 1%.

The steps of the preparation process are the same as in Example 1.

Embodiment 3: (following each raw material percentage composition is weight percent composition)

Soy protein powder 70%

Whey Protein Powder 30%

Soy Isoflavones 0.6%

Fructo-oligosaccharides 4%

Calcium Lactate 2%

Xanthan Gum 0.7%

Lecithin 1%.

The steps of the preparation process are the same as in Example 1.

Animal experiment result of the present invention is as follows:

It has been confirmed by animal experiments that the product of the present invention can obviously prevent the occurrence of osteoporosis in ovariectomized rats. The experimental steps and results are as follows:

1. Animal source and grouping

50 unmated healthy female SD rats, 3.5 months old, weighing 250-280g, were acclimatized in this laboratory for 1 week, and were randomly divided into 5 groups according to body weight, with 10 rats in each group:

(1). Sham operation control group (Sham): Sham operation, that is, the same operation process as ovariectomy, but without removing the ovary, only a small piece of fat was removed, and the protein source of feed was casein;

(2). Ovariectomized control group (Ovx): ovariectomized, feed protein source is casein;

(3). Unenhanced soybean isoflavone group (O-SI): Ovariectomy, feed protein source is ordinary nutritional protein powder without fortified soybean isoflavone;

(4). Medium-dose soybean isoflavone group (M-SI): ovariectomized, feed protein source is nutritional protein powder fortified with soybean isoflavone, and its addition amount is 350mg/100g protein powder;

(5). High-dose soybean isoflavone group (H-SI): the ovariectomized, feed protein source is nutritional protein powder fortified with soybean isoflavone, and the added amount is 760mg/100g protein powder.

Animals in each group had the same basal feed, the temperature of the feeding environment was 20-24°C, the humidity was 40-60%, the light was alternated for 12 hours, and water and food were free to drink. After the operation, the rats recovered for 1 week and entered the formal experiment period. The diet of the animals was observed every day, the body weight was weighed once a week, the feed consumption was recorded every 3 days, and the daily food intake of each group was calculated at the same time. After feeding for 3 months, the rats were fasted for 24 hours, and the rats were sacrificed, and the required samples were collected for functional evaluation.

2. Measuring indicators and methods

The femur bone mineral density of rats was measured by dual-energy X-ray bone density (BMD) instrument; bone calcium was measured by atomic absorption method; bone phosphorus was measured by malachite green-phosphomolybdic acid colorimetric method; serum alkaline phosphatase activity was measured by colorimetric method ; Determination of serum osteocalcin content by competitive radioimmunoassay.

3. Statistical processing

表示，差异显著性以P＜0.05和P＜0.01表示。All data were analyzed and processed with SPSS statistical software, and the results were expressed as mean and standard deviation.

Indicates that the significance of the difference is represented by P<0.05 and P<0.01.

4. Effect of nutritional protein powder on body weight of ovariectomized rats

The general condition of the rats in each group and postoperative wound healing were good without infection. The weight of the five groups of rats all increased, and there was a statistical difference in the weight of the five groups on the 15th day of the experiment. The weight of the ovariectomized control group and the non-enhanced isoflavone group was significantly higher than that of the sham operation group and the isoflavone group, and the difference was statistically significant (P<0.05, Table 1); until the end of the experiment period, the weight of the ovariectomized control group and the non-enhanced isoflavone group was continuously higher than that of the sham operation group, and the difference was statistically significant (P<0.01), while the body weight of the fortified different doses of isoflavone group and the Compared with the sham control group, the body weight did not increase significantly. It shows that nutritional protein powder fortified with soy isoflavones can prevent obesity caused by estrogen deficiency in ovariectomized rats.

)The impact of table 1 nutritional protein powder on the body weight of ovariectomized rats (

)

group Weight (g) Day 1 day 15 Day 45 Day 75 end of experiment ShamOvxO-SIM-SIH-SI 267.539±10.300264.935±12.167265.305±11.189264.774±11.805264.959±9.730 292.604±12.229310.796±10.565 ^a 312.952±10.512 ^a 292.759±13.093285.400±11.529 323.885±16.535351.633±12.500 ^b 360.028+15.356 ^b 345.920±19.302331.443±16.823 330.209±13.413354.326±14.091 ^b 363.849±17.355 ^b 350.323±13.269339.351±11.601 338.780±12.215359.536±13.203 ^b 366.053±16.430 ^b 351.745±15.273341.559±11.392

Note: a Compared with the sham operation group, P<0.05. b Compared with the sham operation group, P<0.01

5. Effect of nutritional protein powder on bone mineral density, bone calcium and bone phosphorus in ovariectomized rats

As can be seen from Table 2, compared with the sham operation group, the bone mineral density of the rats in the ovariectomized control group decreased significantly (P<0.01), down 12.9%. Significantly increased (P<0.05 and P<0.01), compared with the ovariectomized control group, the M-SI group and the H-SI group increased by 5.9% and 12.1%, respectively, and compared with the unenhanced soybean isoflavone group, the M-SI group and the The H-SI group improved by 2.7% and 9.9%, respectively.

Compared with the sham operation group, bone calcium and bone phosphorus in the ovariectomized control group decreased significantly (P<0.01), decreased by 3.8% and 12.7% respectively, while bone calcium and bone phosphorus all increased significantly after giving protein powder fortified with isoflavones ( P<0.01), compared with the ovariectomized control group, bone calcium in different doses of isoflavone groups increased by 4.2% and 4.8%, bone phosphorus increased by 13.1% and 12.7%, respectively, compared with non-enriched soybean isoflavone group The bone calcium content of the two groups increased by 4.6% and 5.2%, respectively, and the bone phosphorus content increased by 11.5% and 11.8%.

The impact of table 2 nutrient protein powder on rat femur bone mineral density and bone calcium, bone phosphorus ( )

group Bone Density (BMD) g/cm ² Bone calcium (Ca) mg/g Bone phosphorus (P)mg/g ShamOvx0-SIM-SIH-SI 0.201±0.0140.175±0.014 ^a 0.181±0.0030.186±0.007 ^bd 0.199±0.010 ^ce 229.363±5.483220.549±6.693 ^a 219.790±3.788229.971±5.729 ^ce 231.136±7.456 ^ce 114.418±10.14199.846±3.206 ^a 100.972±5.876112.928±3.476 ^ce 112.585±9.599 ^ce

Note: a Compared with the sham operation group, P<0.01. b Compared with the ovariectomized control group, P<0.05.c Compared with the ovariectomized control group, P<0.01

dCompared with unfortified soy isoflavone group, P<0 05.eCompared with unfortified soy isoflavone group, P<0.01

6. Effect of nutritional protein powder on serum biochemical indicators of ovariectomized rats

It can be seen from Table 3 that compared with the sham operation group, the serum AKP activity of the rats in the ovariectomized control group decreased significantly (P<0.05), by 12.90%. After being given protein powder fortified with different doses of soybean isoflavones, all of them were significantly improved (P<0.01 and P<0.05), compared with the ovariectomized control group, the M-SI group and the H-SI group increased by 25.00% and 34.79% respectively; Compared with the non-fortified soybean isoflavone group, the M-SI group and H-SI group increased by 10.86% and 19.21%, respectively.

Compared with the sham operation group, the serum BGP content of the ovariectomized control group was significantly increased (P<0.05), an increase of 39.68%; the increase of the serum BGP content was inhibited (P<0.05 ), decreased by 25.77% compared with the ovariectomized control group, and had no significant difference compared with the non-fortified soy isoflavone group; There was no significant difference between the control group and the non-fortified soy isoflavone group.

The impact of table 3 nutritional protein powder on rat serum alkaline phosphatase and osteocalcin ( )

group AKP (King's unit/100ml) BGP(ng/ml) Sham0vx0-SIM-SIH-SI 9.717±3.1947.334±0.789 ^a 8.293±2.0469.194±1.590 ^c 9.886±1.523 ^cd 1.328±0.6091.855±0.315 ^a 1.708±0.6721.377±0.620 ^b 1.641±0.439

Note: a P<0.05 compared with the sham operation group, b P<0.05 compared with the ovariectomized group

c Compared with the ovariectomized group, P<0.01, d Compared with the non-enriched soybean isoflavone group, P<0.05

Definition of AKP unit: 1 mg of phenol produced by 100 ml of serum reacting with the substrate at 37°C for 15 minutes is a King's unit.

7. Conclusion:

In this experiment, the protein powder fortified with soy isoflavones was given to treat the ovariectomized rats for 3 months, and the femoral bone mineral density (BMD), bone calcium and bone phosphorus content of the rats increased significantly (p<0.01), indicating that soy isoflavones It can reverse the bone loss caused by estrogen deficiency and prevent osteoporosis. The increase of bone alkaline phosphatase activity (AKP) and the decrease of osteocalcin (BGP) content in serum indicate that the activity of osteoblasts increases and the rate of bone turnover decreases, which can prevent osteoporosis.

Claims (8)

1. complex nutrition albumen powder that prevents women's osteosporosis after menopause, it is characterized in that: its constituent and percentage by weight thereof are respectively:

Soyabean protein powder 55～80%

PURE WHEY 15～35%

Isoflavones 0.2～0.8%

Compound sugar 1～5%

Calcium lactate 1.2～2.4%

Stabilizing agent 0.5～1%

Lecithin 0.5～1.5%.

2. the complex nutrition albumen powder of prevention women's osteosporosis after menopause according to claim 1 is characterized in that: described soyabean protein powder is a soybean protein isolate, its protein content 〉=60%.

3. the complex nutrition albumen powder of prevention women's osteosporosis after menopause according to claim 1 is characterized in that: described PURE WHEY is a WPC, its protein content 〉=60%.

4. the complex nutrition albumen powder of prevention women's osteosporosis after menopause according to claim 1 is characterized in that: total isoflavone content 〉=40% in the described isoflavones.

5. according to the complex nutrition albumen powder of claim 1 or 4 described prevention women's osteosporosis after menopause, it is characterized in that: the content of described isoflavones is to calculate with total isoflavone content.

6. the complex nutrition albumen powder of prevention women's osteosporosis after menopause according to claim 1 is characterized in that: described compound sugar is soyabean oligosaccharides or oligoisomaltose or FOS or low poly lactose or galactooligosaccharide.

7. the complex nutrition albumen powder of prevention women's osteosporosis after menopause according to claim 1 is characterized in that: described stabilizing agent is xanthans or carragheen, or both mixtures.

8. the complex nutrition albumen powder of prevention women's osteosporosis after menopause according to claim 1 is characterized in that: described lecithin is the lecithin of homogeneous.